Evidence map›Paper›PMID 39931706›Full record

ArticleCirculation reports2025

Prognostic Value of Submaximal Cardiopulmonary Exercise Testing in Patients With Cardiac Amyloidosis.

Robin Willixhofer, Nikita Ermolaev, Christina Kronberger, Mahshid Eslami, Johannes Vilsmeier, René Rettl, Christian Nitsche, Andreas Kammerlander, Jutta Bergler-Klein, Johannes Kastner and 2 more

Abstract read
In one paragraph

Article in Circulation reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Cardiac amyloidosis: what every interventional cardiologist should know.Cardiovascular intervention and therapeutics · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Robin Willixhofer *Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Nikita Ermolaev *Department of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Christina KronbergerDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Mahshid EslamiDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Johannes VilsmeierInstitute for Medical Statistics, Medical University of Vienna Vienna Austria.
René RettlDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Christian NitscheDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Andreas KammerlanderDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Jutta Bergler-KleinDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
Johannes KastnerDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.
David NiederseerHochgebirgsklinik Davos, Medicine Campus Davos Davos Switzerland.
Roza Badr EslamDepartment of Internal Medicine II, Clinical Division of Cardiology, Medical University of Vienna Vienna Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study assessed the prognostic value of submaximal cardiopulmonary exercise testing (CPET) in cardiac amyloidosis and explored CPET as an alternative to the 6-min walk test (6MWT). Methods and Results: In this single-center prospective observational study, 160 patients with cardiac amyloidosis (87% male; mean age 78±7 years) were evaluated. A total of 145 performed maximum symptom limited CPET. The V̇E/V̇CO Conclusions: These findings highlight CPET parameters, particularly V̇E/V̇CO

Indexed as

Cardiac amyloidosisCardiomyopathyCardiopulmonary exercise testing

Identifiers

PMID39931706
PMCPMC11807689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.